JP2011136981A5 - - Google Patents

Download PDF

Info

Publication number
JP2011136981A5
JP2011136981A5 JP2010264759A JP2010264759A JP2011136981A5 JP 2011136981 A5 JP2011136981 A5 JP 2011136981A5 JP 2010264759 A JP2010264759 A JP 2010264759A JP 2010264759 A JP2010264759 A JP 2010264759A JP 2011136981 A5 JP2011136981 A5 JP 2011136981A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
set forth
ttr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010264759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011136981A (ja
Filing date
Publication date
Priority claimed from US10/117,109 external-priority patent/US20030191056A1/en
Application filed filed Critical
Publication of JP2011136981A publication Critical patent/JP2011136981A/ja
Publication of JP2011136981A5 publication Critical patent/JP2011136981A5/ja
Withdrawn legal-status Critical Current

Links

JP2010264759A 2002-04-04 2010-11-29 薬理学的活性ペプチド/タンパク質の血清中半減期を上昇させるためのトランスサイレチンペプチド/タンパク質融合物の使用 Withdrawn JP2011136981A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/117,109 US20030191056A1 (en) 2002-04-04 2002-04-04 Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US10/117,109 2002-04-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003583462A Division JP4738743B2 (ja) 2002-04-04 2003-04-03 薬理学的活性ペプチド/タンパク質の血清中半減期を上昇させるためのトランスサイレチンペプチド/タンパク質融合物の使用

Publications (2)

Publication Number Publication Date
JP2011136981A JP2011136981A (ja) 2011-07-14
JP2011136981A5 true JP2011136981A5 (https=) 2012-03-08

Family

ID=28674128

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003583462A Expired - Fee Related JP4738743B2 (ja) 2002-04-04 2003-04-03 薬理学的活性ペプチド/タンパク質の血清中半減期を上昇させるためのトランスサイレチンペプチド/タンパク質融合物の使用
JP2010264759A Withdrawn JP2011136981A (ja) 2002-04-04 2010-11-29 薬理学的活性ペプチド/タンパク質の血清中半減期を上昇させるためのトランスサイレチンペプチド/タンパク質融合物の使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003583462A Expired - Fee Related JP4738743B2 (ja) 2002-04-04 2003-04-03 薬理学的活性ペプチド/タンパク質の血清中半減期を上昇させるためのトランスサイレチンペプチド/タンパク質融合物の使用

Country Status (9)

Country Link
US (4) US20030191056A1 (https=)
EP (2) EP2298331A3 (https=)
JP (2) JP4738743B2 (https=)
AU (1) AU2003224844B2 (https=)
CA (1) CA2480883A1 (https=)
ES (1) ES2400341T3 (https=)
MX (1) MXPA04009680A (https=)
PL (1) PL372849A1 (https=)
WO (1) WO2003086444A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
WO2005074460A2 (en) * 2003-12-05 2005-08-18 Becton Dickinson And Company Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
MXPA06006745A (es) * 2003-12-18 2006-08-18 Novo Nordisk As Compuestos glp-1 novedosos.
WO2005077976A2 (en) * 2004-02-13 2005-08-25 Avidis Sa Coiled-coil domains from c4b-binding protein
WO2006010057A2 (en) * 2004-07-08 2006-01-26 Amgen Inc. Therapeutic peptides
CN100344323C (zh) * 2004-09-30 2007-10-24 华东师范大学 一种人胰高血糖素样肽-1的复合物及其制备方法
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EA011166B1 (ru) * 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PL1767545T3 (pl) 2005-09-22 2010-04-30 Biocompatibles Uk Ltd Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Glp−1のポリマ複合体
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
EA036772B1 (ru) 2008-10-20 2020-12-18 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
US20120101021A1 (en) 2009-02-06 2012-04-26 Surendra Sharma Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
EP2408814B1 (en) 2009-03-20 2018-11-21 Amgen Inc. Carrier immunoglobulins and uses thereof
US20120231013A1 (en) 2009-07-31 2012-09-13 Black Roy A Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
US8999343B2 (en) 2010-08-16 2015-04-07 Amgen Inc. Antibodies that bind myostatin, compositions and methods
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
CA2830065A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
JP2014132832A (ja) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体
EP2780690A4 (en) * 2011-11-18 2015-12-09 Alnylam Pharmaceuticals Inc QUANTIFICATION OF TRANSTHYRETIN AND ITS ISOFORMS
HUE048622T2 (hu) 2011-11-18 2020-08-28 Alnylam Pharmaceuticals Inc RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
EP2970483A2 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
CA2935903A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
EP3186276B1 (en) 2014-08-27 2019-07-10 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
MY188430A (en) 2015-04-10 2021-12-08 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
CN108138182B (zh) 2015-07-31 2022-08-19 阿尔尼拉姆医药品有限公司 甲状腺素运载蛋白(TTR)iRNA组合物及其治疗或预防TTR相关疾病的使用方法
WO2017155981A1 (en) * 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
CN108623690A (zh) * 2017-03-16 2018-10-09 兰州大学 一种促血小板生成素的融合蛋白及其制备方法和应用
CN106977609B (zh) * 2017-04-19 2020-07-28 刘崇东 一种融合蛋白、制备方法及其应用
FI3661562T3 (fi) 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä
KR20250046363A (ko) 2017-09-19 2025-04-02 알닐람 파마슈티칼스 인코포레이티드 트랜스타이레틴(ttr) 매개 아밀로이드증을 치료하기 위한 조성물 및 방법
US12269898B2 (en) 2017-10-04 2025-04-08 Amgen Inc. Transthyretin immunoglobulin fusions
CN114174334A (zh) 2019-03-22 2022-03-11 反射制药有限公司 针对vegf的d-肽化合物
CN114144433A (zh) 2019-03-22 2022-03-04 反射制药有限公司 用于目标蛋白的多价d-肽化合物
JP7360142B2 (ja) * 2019-05-21 2023-10-12 国立大学法人 熊本大学 アミロイドーシス治療薬の新規スクリーニング方法
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
EP3997112A1 (en) 2019-07-08 2022-05-18 Amgen, Inc Multispecific transthyretin immunoglobulin fusions
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
AU2020328038B2 (en) 2019-08-13 2025-10-09 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CN110960687A (zh) * 2019-12-17 2020-04-07 上海卡序生物医药科技有限公司 转甲状腺素蛋白转运融合蛋白进入眼内的应用
EP3988122A4 (en) * 2019-12-17 2023-01-18 Yizhou (Shanghai) Biological Medicine Co, Ltd. USE OF TRANSTHYRETIN FOR INTRODUCTION TO THE EYE AND MAKING DROPS
EP4208474A2 (en) 2020-09-01 2023-07-12 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
CN114558112B (zh) * 2020-09-16 2024-07-26 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
CA3227852A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS5923252A (ja) * 1982-07-30 1984-02-06 Fuji Photo Film Co Ltd チロキシンの蛍光測定もしくは比色による定量分析法
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
RU2212411C2 (ru) 1989-10-16 2003-09-20 Эмджен Инк. Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
BR9007883A (pt) 1989-11-29 1992-09-29 Synergen Inc Producao de inibidor de interleucina-1 humana recombinante
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DK0578774T3 (da) 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
IT1255439B (it) 1992-07-17 1995-10-31 Getters Spa Pompa getter non evaporabile
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
US5786331A (en) 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
SK100896A3 (en) 1994-02-14 1997-10-08 Zymogenetics Inc Hematopoietic protein and materials and methods for making it
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
JPH09509428A (ja) * 1994-02-23 1997-09-22 カイロン コーポレイション 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物
CN1229385C (zh) 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
US5532166A (en) * 1994-04-18 1996-07-02 Ma; Yinfa Quantitative retinol assay for serum and dried blood spots
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5581005A (en) 1995-06-16 1996-12-03 The Procter & Gamble Company Method for manufacturing cobalt catalysts
GB2302559B (en) 1995-06-23 1998-06-03 Draftex Ind Ltd Opening arrangements and methods for closure members
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
AU6688896A (en) 1995-08-17 1997-03-12 Amgen, Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
WO1998028427A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
PT1783222E (pt) 1998-10-23 2012-07-26 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
CA2399940A1 (en) * 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
WO2002059621A2 (en) * 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
EP1567178A4 (en) * 2002-11-01 2009-07-15 Amgen Inc MODULATORS OF RECEPTORS FOR NEUTRAL THERAPY HORMONE AND SIDE-HORSE HORMONE-RELATED PROTEINS

Similar Documents

Publication Publication Date Title
JP2011136981A5 (https=)
JP2011182796A5 (https=)
JP2011168603A5 (https=)
JP2012520430A5 (https=)
JP2011515062A5 (https=)
JP2011155981A5 (https=)
JP2010534684A5 (https=)
JP2011520976A5 (https=)
JP2013510581A5 (https=)
JP2010088434A5 (https=)
JP2012081521A5 (https=)
JP2014102408A5 (https=)
JP2012042477A5 (https=)
JP2014028813A5 (https=)
JP2015513533A5 (https=)
JP2010065037A5 (https=)
JP2013515360A5 (https=)
JP2009541403A5 (https=)
JP2012034696A5 (https=)
JP2011508438A5 (https=)
JP2010219032A5 (https=)
JP2013500200A5 (https=)
JP2013532130A5 (https=)
JP2013540702A5 (https=)
JP2010265269A5 (https=)